Evidence map›Paper›PMID 22508310›Full record

ArticleAntimicrobial agents and chemotherapy2012

The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.

Bing Zhai, Cheng Wu, Linqi Wang, Matthew S Sachs, Xiaorong Lin

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01802385 (Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis), which is not on this map. Cited by 125 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01802385 phase3completednot on this mapstarted 2015, after this paper: background citation

Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis

TypeinterventionalSponsorUniversity of MinnesotaRan2015 to 2017Enrolled460ConditionsCryptococcal Meningitis, Fungal MeningitisArmsSertraline
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Treatment for HIV-associated cryptococcal meningitis.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. A review of the current anti-New microbes and new infections · 2026
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bing ZhaiDepartment of Biology, Texas A&M University, College Station, Texas, USA.
Cheng Wu
Linqi Wang
Matthew S Sachs
Xiaorong Lin
Texas A&M University · US

Funding

CONTROL OF ARG-2 GENE EXPRESSION IN NEUROSPORAR01GM047498 · NIGMS · TEXAS A&M UNIVERSITY · PI SACHS, MATTHEW STEVEN · 1997 to 2009
$2.8M
The link between dimorphism and virulence in CryptococcusR01AI097599 · NIAID · UNIVERSITY OF GEORGIA · PI LIN, XIAORONG · 2012 to 2016
$1.8M
NIAID NIH HHS R01 AI097599NIGMS NIH HHS R01 GM047498NIGMS NIH HHS R01 GM47498
6 · The paper itself

Abstract

Therapeutic treatment for systemic mycoses is severely hampered by the extremely limited number of antifungals. The difficulty of treatment of fungal infections in the central nervous system is further compounded by the poor central nervous system (CNS) penetration of most antifungals due to the blood-brain barrier. Only a few fungistatic azole drugs, such as fluconazole, show reasonable CNS penetration. Here we demonstrate that sertraline (Zoloft), the most frequently prescribed antidepressant, displays potent antifungal activity against Cryptococcus neoformans, the major causative agent of fungal meningitis. In in vitro assays, this neurotropic drug is fungicidal to all natural Cryptococcus isolates tested at clinically relevant concentrations. Furthermore, sertraline interacts synergistically or additively with fluconazole against Cryptococcus. Importantly, consistent with our in vitro observations, sertraline used alone reduces the brain fungal burden at an efficacy comparable to that of fluconazole in a murine model of systemic cryptococcosis. It works synergistically with fluconazole in reducing the fungal burden in brain, kidney, and spleen. In contrast to its potency against Cryptococcus, sertraline is less effective against strains of Candida species and its interactions with fluconazole against Candida strains are often antagonistic. Therefore, our data suggest the unique application of sertraline against cryptococcosis. To understand the antifungal mechanisms of sertraline, we screened a whole-genome deletion collection of Saccharomyces cerevisiae for altered sertraline susceptibility. Gene ontology analyses of selected mutations suggest that sertraline perturbs translation. In vitro translation assays using fungal cell extracts show that sertraline inhibits protein synthesis. Taken together, our findings indicate the potential of adopting this antidepressant in treating cryptococcal meningitis.

Indexed as

AnimalsAntidepressive AgentsCryptococcosisCryptococcus neoformansFemaleFluconazoleMiceMicrobial Sensitivity TestsSaccharomyces cerevisiaeSertralineAntidepressive AgentsFluconazoleSertraline

Identifiers

PMID22508310
PMCPMC3393448
OpenAlexW2172160469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.